- Home
- CRIS vs GDTC Comparison
CRIS vs GDTC Comparison
Compare CRIS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- GDTC
- Stock Information
- Founded
- CRIS 2000
- GDTC 2018
- Country
- CRIS United States
- GDTC Singapore
- Employees
- CRIS N/A
- GDTC N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- GDTC Health Care
- Exchange
- CRIS Nasdaq
- GDTC Nasdaq
- Market Cap
- CRIS 22.9M
- GDTC 21.5M
- IPO Year
- CRIS 2000
- GDTC 2023
- Fundamental
- Price
- CRIS $1.67
- GDTC $1.88
- Analyst Decision
- CRIS Strong Buy
- GDTC Buy
- Analyst Count
- CRIS 2
- GDTC 1
- Target Price
- CRIS $16.50
- GDTC $5.00
- AVG Volume (30 Days)
- CRIS 76.7K
- GDTC 14.8K
- Earning Date
- CRIS 11-13-2025
- GDTC 01-01-0001
- Dividend Yield
- CRIS N/A
- GDTC N/A
- EPS Growth
- CRIS N/A
- GDTC N/A
- EPS
- CRIS N/A
- GDTC N/A
- Revenue
- CRIS $11,405,000.00
- GDTC $368,838.00
- Revenue This Year
- CRIS $1.41
- GDTC $5.37
- Revenue Next Year
- CRIS $7.46
- GDTC N/A
- P/E Ratio
- CRIS N/A
- GDTC N/A
- Revenue Growth
- CRIS 12.24
- GDTC N/A
- 52 Week Low
- CRIS $1.02
- GDTC $1.20
- 52 Week High
- CRIS $6.44
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- CRIS 45.61
- GDTC 46.04
- Support Level
- CRIS $1.63
- GDTC $1.82
- Resistance Level
- CRIS $1.95
- GDTC $2.28
- Average True Range (ATR)
- CRIS 0.15
- GDTC 0.12
- MACD
- CRIS 0.00
- GDTC 0.00
- Stochastic Oscillator
- CRIS 17.65
- GDTC 13.04
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.